Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Surgery
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Surgery
    Abdominal Surgery Incision Method Has No Affect on Healing Process, Pain - (DGNews)
    Bone-Morphogenetic Protein Associated With More Complications in Spinal Fusions - (DGNews)
    Screening men for abdominal aortic aneurysm: 10 year mortality and cost effectiveness results from the randomised Multicentre Aneurysm Screening Study - (BMJ)
    Bariatric Surgery Could Lower Cancer Risk in Obese Women - (DGNews)
    Roux-en-Y Weight Loss Surgery Raises Kidney Stone Risk - (DGNews)

    News archive

     Recent webcasts/CME - Surgery
      Advances in the Management of Postoperative Ileus: Reducing the Clinical and Economic Burden
      Occipital Fusion Techniques
      Perioperative Management Strategies for the Patient Requiring Warfarin
      Posterior Dynamic Stabilization of the Thoracolumbar Spine
      Causes and Risk Factors for Postoperative Fever in Spine Surgery Patients

      Webcasts/CME archive

       Recent cases - Surgery
        Malignant Teratoma of the Uterine Corpus
        Spontaneous Regression in Alveolar Soft Part Sarcoma: Case Report and Literature Review
        Ectopic Pancreatic-Type Malignancy Presenting in a Meckel's Diverticulum: A Case Report and Review of the Literature
        Abnormal Presentation of Pulmonary Langerhans Cell Histiocytosis
        Successful Management of an Aortoesophageal Fistula Caused by a Fish Bone - Case Report and Review of Literature

        Cases archive
          




        my personal edition > surgery > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Intralesional Bacille Calmette-Guerin Injection Effective for Melanoma but Underused: Presented at ACS

        By Crystal Phend

        SAN FRANCISCO, CA -- October 24, 2005 -- Although intralesional injections of bacilli Calmette-Guerin (BCG) have fallen into disuse for melanoma, they are effective and have manageable toxicity, according to results of a 40-year prospective study.

        Mark B. Faries, MD, Surgical Oncologist and Director of Translational Tumor Immunology, John Wayne Cancer Institute, Santa Monica, California, United States, presented the findings here October 19th at the American College of Surgeons (ACS) annual meeting.

        "Intralesional BCG generates a vigorous immune response, good local control and complete [disease] regression in 80% [of patients]," Dr. Faries said. "Systemic immunity may also develop in these patients."

        This treatment was first used nearly 35 years ago, but due to early concerns of systemic infection and two reported deaths, alternative approaches such as isolated limb perfusion and systemic therapy are used more commonly.

        Dr. Faries and colleagues examined records of 547 melanoma patients treated with intralesional BCG in a prospectively collected clinical database and also conducted a retrospective assessment of records from 52 recently treated patients.

        In the total cohort, almost half of patients had clinical stage III melanoma (47%) while 28% had stage I/II disease and 25% had stage IV disease.

        These patients had a median survival of 15.4 months and a 5-year survival rate of 20%. BCG treatment alone achieved a local control rate of 56%. Local control was attained with simple excision or ablation in 19% and after conversion to intralesional interferon alpha in 4% of patients.

        Eighty percent of the lesions with evaluable responses regressed completely with BCG and another 11% stabilized or partially regressed and were excised; 9% progressed.

        Immunological response as measured by purified protein derivative conversion was a significant predictor of overall survival.

        The cohort had mostly stage III melanoma (73%) with phase I/II accounting for about 12% of patients and stage IV disease for about 15%.

        The researchers found that dose was dependent on PPD status, typically about 0.1 to 0.2 cc per lesion.

        Toxicity was typically erythema, induration and ulceration. Fever occurred in 22% of the 52 cases reviewed, flu-like symptoms in 10%, cellulitis in 4% and cough in 2%.

        One patient (2%) required hospitialization for suspected disseminated BCG infection (BCGosis) and two patients treated at other centers had systemic infections. All recovered with antitubercular medication.

        The researchers acknowledged that a limitation of their study is that dosing changed throughout the 40-year study period, among other possible confounders.

        More detailed investigations of systemic immunity with BCG treatment are needed, Dr. Faries said, but concluded, "In our experience, intralesional BCG has been very safe and effective."


        [Presentation title: Intralesional Bacillus Calmette-Guerin Immunotherapy in Metastatic Melanoma: An Effective but Underutilized Therapy. General Session 63]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send